Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Sarcoma 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1

Interventions

pembrolizumab 512Specimen Handling 381Carboplatin 371Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 302Cyclophosphamide 295Radiotherapy 254Paclitaxel 252Biopsy 235Gemcitabine 229Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 154Rituximab 151Fluorouracil 148venetoclax 142atezolizumab 141Docetaxel 141Drug Therapy 140Etoposide 138Doxorubicin 131Ipilimumab 125Radiosurgery 118Lenalidomide 117Prednisone 116Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × STA 9090 × 1 year × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
50 enrolled 14 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡